Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
The number of people with Parkinson's disease is expected to grow to 14.2 million by 2040 due to increasing life expectancy and population aging. The medical community must mobilize to respond to this growing public health threat, advocating for increased research funding, access to care, and affordable treatments.
Studies show that gut-derived metabolites may prevent neurodegeneration, while probiotic treatment corrects memory problems in an Alzheimer's mouse model. The research suggests targeting the gut could be a promising angle to tackle brain disorders across the lifespan.
A four-year study investigates how long-term exposure to airborne particulates relates to Parkinson's onset later in life, exploring the role of nasal inflammation and anti-inflammatory medications. The team aims to develop ways to evaluate an individual's risk for the disease and therapies to prevent or slow its progression.
A recent study by Korean researchers identified a potential mechanism of licorice extract inhibiting dopaminergic neuronal cell death in Parkinson's disease. The study found that liquiritigenin, a compound extracted from licorice, induces the expression of RNF146 protein and removes excessive PAR accumulation, resulting in inhibition o...
Researchers are investigating a novel treatment approach for Parkinson's disease by inhibiting the protein Bach1, which blocks the body's natural protection against oxidative stress. By removing Bach1, scientists aim to restore balance and promote the activation of neuroprotective genes.
A new study by OHSU researchers suggests that performing brain surgery on patients who are asleep can produce comparable or even better clinical outcomes than procedures conducted while the patient is awake. This approach has improved speech fluency and reduced motor function issues for patients undergoing deep-brain stimulation. The s...
A small pilot study found that focused ultrasound treatment improved hand tremor by up to 62% in participants with Parkinson's disease, with minimal side effects. Further research is needed to confirm the effectiveness and potential role of this scalpel-free surgery approach.
Researchers at City College of New York are exploring Sonic Hedgehog as a potential treatment for Parkinson's Disease. They have found that dopamine neurons secrete SHH, which can help reduce symptoms like dyskinesia, and are now testing Smoothened agonists in both mice and macaques.
Researchers found that LRRK2 is necessary for the survival of dopamine-containing neurons in the brain, which are affected by Parkinson's disease. The study could alter treatment approaches against the disease.
Scientists used a novel gene editing technique to uncover the genetic basis of paraquat-induced Parkinson's disease. The study identified three genes - POR, ATP7A and SLC45A4 - that confer resistance to paraquat, suggesting these genes may be responsible for the toxicity.
Researchers are studying the relationship between gut bacteria and Parkinson's disease, aiming to identify early signs of the illness. The study aims to compare the gut bacteria of people in the earliest stages of the disease with those who are healthy.
Researchers have unraveled a direct link between LRRK2 protein dimerization and genetic mutations in Parkinson's disease. This process could lead to a promising new therapy route, as the kinase inhibitor causes lung and kidney problems.
The study highlights the growing impact of neurological disorders on global health, with increased deaths and disabilities over the past 25 years. The most prevalent disorders are tension-type headaches, migraine, and Alzheimer's disease, which have seen significant increases in cases and DALYs.
Researchers at the University of Dundee have identified the 3D structure and inner workings of the PINK1 enzyme, a key player in protecting brain cells against stress. This breakthrough provides crucial insights into how PINK1 exerts its protective role in Parkinson's disease.
Researchers found Parkinson's disease reduces olfactory bulb glomerular volume by over half and alters their distribution, suggesting a key role for Lewy bodies in triggering the disease. The study provides new insights into the anatomical link between Parkinson's disease and impaired sense of smell.
Research shows carbidopa, an FDA-approved Parkinson's disease drug, has anticancer properties. The study found that carbidopa significantly inhibits cancer cell growth in both human pancreatic cancer cells and mouse models, suggesting potential as an anticancer medication.
A computational study models the strength of basal ganglia connections between healthy and Parkinsonian brains, revealing a broad overlap in neural connection strengths. The research could lead to customized therapies specific to individual patterns of neural degeneration.
Research found disconnections in brain areas involved in attention and visual processing may contribute to visual hallucinations in individuals with Parkinson's disease. The study used fMRI to examine connectivity between brain areas, showing decreased synchronization in patients with visual hallucinations.
A study of 121 people with Parkinson's disease found that consuming three cups of coffee per day did not improve movement symptoms. The researchers concluded that caffeine cannot be recommended as therapy for movement symptoms of Parkinson's disease.
A KAIST research team has identified a new mechanism that causes the hallmark symptoms of Parkinson's disease, including tremors. The discovery presents a new perspective on three decades of conventional wisdom and opens up new avenues for alleviating motor problems.
Researchers have discovered a novel molecular pathway that interacts with prion protein, triggering neuronal dysfunction and cognitive impairments in Parkinson's disease. The study provides new targets for therapeutic intervention.
Researchers discovered that alpha-synuclein, a protein involved in Parkinson's disease, blocks signals from the important brain growth factor BDNF. This 'tug of war' between alpha-synuclein and BDNF affects brain cells' survival and explains why dopamine-producing neurons are more vulnerable to degeneration.
A unique mutation in the ACMSD gene has been identified in a 74-year-old man with Parkinson's disease, which may be linked to an increased risk of neurodegeneration. This discovery could lead to a better understanding of the disease and potentially inform the development of new therapeutic strategies.
Researchers found that Parkinson's disease may be caused by maladaptive brain rewiring in the subthalamic nucleus, leading to impaired movement. The study challenges the traditional understanding of brain dysfunction in Parkinson's disease.
Researchers have identified a toxic cascade in Parkinson's disease and found that treating dopamine neurons with antioxidants early on may prevent degeneration and improve neuron function. The study also highlights the importance of studying human neurons to develop new therapies.
Researchers found that intermittent electrical stimulation improved working memory in adult non-human primates, whereas continuous deep brain stimulation impaired memory. The study suggests that increased acetylcholine levels and blood flow may contribute to the benefits of intermittent stimulation.
Researchers have developed a new diagnostic software that can detect Parkinson's disease in its earliest stages, using readily available technologies. The tool records how a person draws a spiral and analyzes the data to calculate the severity of the condition with 93% accuracy.
A team of researchers in Australia developed an automatic system to diagnose Parkinson's disease severity from drawing speed and pen pressure measurements. The system combines these metrics into a single measurement, the Composite Index of Speed and Pen-pressure score, allowing for accurate diagnosis and monitoring of treatment effects.
A study published in Neurology found that a scratch-and-sniff test may predict Parkinson's disease up to six years before diagnosis. The test showed strong links between smell and disease risk for white participants, but weaker associations for black participants. Older men with poor sense of smell were more likely to develop the disease.
A study found that older adults with poor sense of smell are more likely to develop Parkinson's disease than those who perform better on the test. The researchers also found a stronger link between poor smell and disease in men, but not in women. The test could help identify people at greater risk up to six years before diagnosis.
Researchers found that an antidepressant drug, nortriptyline, slowed the growth of abnormal proteins associated with Parkinson's disease. The study suggests a potential new approach to treating the disease, which could be simpler and more effective than current therapies.
A new pathway to target Parkinson's disease has been identified, leveraging beta2-adrenergic agonists that lower alpha-synuclein production. Studies in mice and human health records suggest a 34% reduced PD risk for patients taking salbutamol.
Researchers at the University of Bergen have found that asthma medicine can halve a patient's risk of developing Parkinson's disease. The study analyzed over 100 million Norwegian prescriptions and discovered a link between asthma medicine and reduced Parkinson's risk.
A new clinical investigation is testing whether genetic screening can identify patients with a specific mutation who are the best candidates for deep brain stimulation surgery. The study aims to determine how this genetic information can inform surgical decisions and potentially improve outcomes for Parkinson's disease patients.
Researchers identified beta-2 adrenergic receptor agonists as compounds that can suppress alpha-synuclein gene expression, reducing the genetic risk factor for Parkinson's disease. The findings suggest that widely used beta-2AR agonists should be rigorously tested in PD patients.
Researchers found a difference in gut bacteria between Parkinson's patients and healthy individuals even at an early stage of the disease. Certain microbes are associated with non-motor symptoms like depression. The study aims to better understand the microbiome's role in the disease.
Researchers review neuroinflammation as a key factor in Alzheimer's and Parkinson's diseases, highlighting four modifiable risk factors: physical inactivity, vascular disease-related conditions, obesity, and type two diabetes mellitus. Controlling these risk factors may help manage the increasing incidence of both diseases.
Researchers at Arizona State University have developed an early blood test for Alzheimer's disease that can detect the disease before symptoms appear. The test distinguishes between Alzheimer's, Parkinson's, and healthy controls by analyzing RNA transcripts in white blood cells.
The Blink Reflexometer device detects changes in blinking patterns to identify concussions and neurological disorders like Parkinson's, Huntington's, and schizophrenia. The technology aims to provide a portable, rugged, and fast aid for trainers to make objective calls about player safety.
A new study by the American Academy of Neurology found that telemedicine is as effective as traditional in-person care for people with Parkinson's disease. Virtual house calls provided convenience and comfort without compromising quality of life.
A nationwide program showed that telemedicine can deliver quality care to people with Parkinson's disease in their homes via video conferencing. The study found that virtual house calls were as effective as in-person visits, saving patients time and travel, while improving access to care for those with limited mobility.
A team of scientists at UC San Diego has found that lysosomes can travel to distant parts of neurons' dendrites and branch-like areas, playing a key role in remodeling and plasticity. This discovery may provide new insights into the development of neurodegenerative diseases.
A new study published in The Lancet suggests that a diabetes drug may have disease-modifying potential to treat Parkinson's disease, improving motor function in patients. Researchers found that people with Parkinson's who used exenatide for one year performed better in movement tests than those who injected a placebo.
Researchers at Binghamton University have developed a new drug that demonstrates superior anti-parkinsonian efficacy over current medications. The compound, D-512, provides longer symptom relief and prolongs the time window in which benefits are shown.
Researchers developed a smartphone-based biofeedback rehabilitation system to guide patients through balance exercises, showing noticeable improvements in postural stability and reducing the risk of falls. The custom wearable belt uses vibrating actuators to provide personalized guidance, mapped in real-time on a smartphone application.
Researchers found that T cells from people with PD responded to alpha-synuclein to a greater degree than those gathered from healthy controls. Four genetic variations were associated with T cell reactivity, and over half of people with PD carried at least one variant.
Researchers found that fluid changes in a specific brain area could provide a way to track Parkinson's damage, with increased free water linked to worsening symptoms and progressive degeneration of neurons.
A team of researchers has successfully manufactured microscopic versions of silkworm cocoons, which can store and protect sensitive molecular materials. The tiny capsules, made from silk nano-fibrils, have the potential to increase the stability and lifetime of antibodies used in pharmaceuticals for treating severe diseases.
A study found significant abnormalities in Parkinson's disease patients' visual systems, including optic radiations alterations and white matter concentration reductions. These changes may serve as biomarkers for early detection and monitoring of the disease.
Researchers found that patients with Parkinson's were four times more likely to have a history of melanoma than those without the disease. In contrast, people with melanoma had a fourfold higher risk of developing Parkinson's. The study suggests that common environmental or genetic factors may underlie both conditions.
Researchers found that the AEP enzyme trims alpha-synuclein into toxic pieces, similar to its effect on tau in Alzheimer's disease. This discovery offers a potential drug target for Parkinson's disease.
A clinical trial found that noninvasive brain stimulation and physical therapy alone or in combination improve some measures of walking ability in patients with Parkinson's disease. Walking speed increased by an average of 19 percent, with improvements lasting for at least eight weeks after treatment.
Scientists at Georgetown University Medical Center found that alpha-Synuclein, a protein implicated in Parkinson's disease, is released when an infection occurs in the upper GI tract, inducing an immune response. Chronic infections may overwhelm the body's capacity to clear alpha-Synuclein, leading to disease.
Researchers have discovered that correct connections between brain regions are essential for optimal relief of Parkinson's Disease symptoms using deep brain stimulation. By analyzing brain connectivity, they were able to predict the best possible outcome and optimize electrode placement.
Researchers found that autoimmunity plays a role in Parkinson's disease, where the immune system attacks the body's own tissues. The study identified alpha-synuclein protein as a trigger for immune response, raising hope for new diagnostic tests and therapies to prevent neuronal death.
A newly developed research tool may help predict a patient's risk for developing dementia in Parkinson's disease, enabling improved clinical trial design and treatment development. A computer-based risk calculator was built from data on 3,200 people with Parkinson's disease, evaluating seven known risk factors.
A new research tool may predict a patient's risk for developing dementia in Parkinson's disease, enabling the design of 'smarter' trials that require fewer participating patients. The tool was built using data from 3,200 people with PD and evaluates seven known clinical and genetic risk factors.
Duke University researchers have identified a potential new mechanism for Parkinson's disease, suggesting that misfolded alpha-synuclein protein spreads from gut endocrine cells to the brain. This finding could lead to earlier diagnosis and development of therapies targeting the protein.
Researchers analyzed data from over 50 million people and found that prior statin use was associated with a higher risk of developing Parkinson's disease. The association was more noticeable in people taking lipophilic statins, and was most robust for those using the medication for less than two-and-a-half years.
A recent study published in PLOS Medicine suggests that genetic variants associated with higher body mass index (BMI) are linked to lower risk of Parkinson disease. The researchers used a Mendelian randomization approach to examine the relationship between BMI and Parkinson disease, and found an 18% lower risk of Parkinson disease amon...